title: A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
abstract: Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield. We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin's lymphoma. Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab. There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation.
authors.affiliation: Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA. copelae@ccf.org
authors.forename: E
authors.initials: E
authors.lastname: Copelan
authors.forename: B
authors.initials: B
authors.lastname: Pohlman
authors.forename: L
authors.initials: L
authors.lastname: Rybicki
authors.forename: M
authors.initials: M
authors.lastname: Kalaycio
authors.forename: R
authors.initials: R
authors.lastname: Sobecks
authors.forename: S
authors.initials: S
authors.lastname: Andresen
authors.forename: R
authors.initials: R
authors.lastname: Dean
authors.forename: A
authors.initials: A
authors.lastname: Koo
authors.forename: J
authors.initials: J
authors.lastname: Chan
authors.forename: J
authors.initials: J
authors.lastname: Sweetenham
authors.forename: B
authors.initials: B
authors.lastname: Bolwell
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34 / Q000096:biosynthesis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069283:Rituximab; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D005047:Etoposide